Please login to the form below

Not currently logged in
Email:
Password:

GSK pneumococcal vaccine to be reviewed by EMEA

GlaxoSmithKline has announced its pneumococcal paediatric vaccine Synflorix has been accepted for review by the European Medicines Agency.

GlaxoSmithKline (GSK) has announced its pneumococcal paediatric vaccine Synflorix has been accepted for review by the European Medicines Agency (EMEA).

The vaccine is designed to protect children against both invasive pneumococcal disease (IPD) and bacterial respiratory infections such as acute middle ear infections (otitis media).

Acute middle ear infections is one of the most frequent childhood diseases and the most frequent indication for prescribing of antibiotics.

GSK says it uses a breakthrough approach in pneumococcal vaccine technology with this vaccine. It has been designed with an active carrier protein to induce protection against non-typeable Haemophilus influenzae (NTHi) in addition to Streptococcus pneumoniae.

Jean Stèphenne, president of GSK Biologicals, said "We are very pleased with this important step towards the introduction of this vaccine, which is designed to offer a broad protection against pneumococcal disease and a dual pathogen protection against otitis media caused by Strep pneumoniae and non-typeable Haemophilus influenzae. If approved, this vaccine could further reduce the mortality due to invasive pneumococcal disease and also the significant morbidity associated with a more frequent disease in children, namely otitis media."

According to VacZine Analytics, a UK-based strategic research agency, GSK's pending new vaccine, (as well as Wyeth which is also looking into the next generation of pneumococcal vaccines) makes it incredibly difficult to enter the near-term market for pneumococcal vaccines despite its huge long-term potential.

For this reason other companies such as Sanofi- Pasteur and Novartis, have been experimenting with protein based-antigens that might provide universal coverage and avoid the complex and expensive protein-polysaccharide manufacturing process associated with current vaccines.

31st January 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics